EE03337B1 - Fast soluble galantamine hydrobromide tablet - Google Patents

Fast soluble galantamine hydrobromide tablet

Info

Publication number
EE03337B1
EE03337B1 EE9800429A EE9800429A EE03337B1 EE 03337 B1 EE03337 B1 EE 03337B1 EE 9800429 A EE9800429 A EE 9800429A EE 9800429 A EE9800429 A EE 9800429A EE 03337 B1 EE03337 B1 EE 03337B1
Authority
EE
Estonia
Prior art keywords
galantamine hydrobromide
fast soluble
hydrobromide tablet
tablet
soluble
Prior art date
Application number
EE9800429A
Other languages
Estonian (et)
Inventor
Florent Victor De Cond Valentin
Marie Victor Gilis Paul
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of EE03337B1 publication Critical patent/EE03337B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EE9800429A 1996-06-14 1997-06-06 Fast soluble galantamine hydrobromide tablet EE03337B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96201676 1996-06-14
PCT/EP1997/002986 WO1997047304A1 (en) 1996-06-14 1997-06-06 Fast-dissolving galanthamine hydrobromide tablet

Publications (1)

Publication Number Publication Date
EE03337B1 true EE03337B1 (en) 2001-02-15

Family

ID=8224084

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9800429A EE03337B1 (en) 1996-06-14 1997-06-06 Fast soluble galantamine hydrobromide tablet

Country Status (33)

Country Link
US (2) US6099863A (en)
EP (1) EP0915701B1 (en)
JP (1) JP4172820B2 (en)
KR (1) KR100358676B1 (en)
CN (1) CN1102390C (en)
AR (2) AR008237A1 (en)
AT (1) ATE285777T1 (en)
AU (1) AU726212B2 (en)
BG (1) BG64168B1 (en)
BR (1) BR9709729A (en)
CA (1) CA2257431C (en)
CZ (1) CZ295226B6 (en)
DE (1) DE69732113T2 (en)
DK (1) DK0915701T3 (en)
EA (1) EA001193B1 (en)
EE (1) EE03337B1 (en)
ES (1) ES2235234T3 (en)
HK (1) HK1019703A1 (en)
HR (1) HRP970321B1 (en)
ID (1) ID17088A (en)
IL (1) IL127519A (en)
MY (1) MY121669A (en)
NO (1) NO322892B1 (en)
NZ (1) NZ333280A (en)
PL (1) PL189329B1 (en)
PT (1) PT915701E (en)
SI (1) SI0915701T1 (en)
SK (1) SK284620B6 (en)
TR (1) TR199802592T2 (en)
TW (1) TW506836B (en)
UA (1) UA62930C2 (en)
WO (1) WO1997047304A1 (en)
ZA (1) ZA975281B (en)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
TW506836B (en) * 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet
OA11740A (en) * 1998-12-24 2005-05-13 Janssen Pharmaceutica Nv Controlled release galantamine composition.
US20050063998A1 (en) * 1999-10-26 2005-03-24 Francois Marc Karel Jozef Oral solution containing galantamine and a sweetening agent
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
AU2001257022B2 (en) * 2000-04-13 2005-02-03 Mayo Foundation For Medical Education And Research Abeta 42 lowering agents
SE521512C2 (en) * 2001-06-25 2003-11-11 Niconovum Ab Device for administering a substance to the front of an individual's oral cavity
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US6500454B1 (en) * 2001-10-04 2002-12-31 Eurand Pharmaceuticals Ltd. Timed, sustained release systems for propranolol
DE10235556A1 (en) * 2002-08-03 2004-02-19 Hf Arzneimittelforschung Gmbh Medicament for treating substance cravings, especially alcohol and/or tobacco abuse, comprising separate dosage forms for continuous release of nicotinic receptor modulator and rapid delivery of galanthamine
US20040097484A1 (en) * 2002-11-14 2004-05-20 Marc Cantillion Once a day galantamine pharmaceutical compositions and methods of use
JP4708795B2 (en) * 2002-12-20 2011-06-22 ニコノヴァム エービー Physically and chemically stable nicotine-containing particulate matter
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
EP1603548A4 (en) * 2003-02-05 2007-10-10 Myriad Genetics Inc Method and composition for treating neurodegenerative disorders
US7521481B2 (en) * 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
DE10338544B4 (en) * 2003-08-19 2017-08-31 Janssen Pharmaceutica N.V. Buccal formulations of galanthamine and their applications
HUE024906T2 (en) * 2003-08-26 2016-02-29 Shire Biopharmaceuticals Holdings Ireland Ltd Pharmaceutical Formulation Comprising Lanthanum Compounds
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
WO2005051489A2 (en) * 2003-11-28 2005-06-09 Ranbaxy Laboratories Limited Fast dissolving solid oral dosage forms of galanthamine
CA2551946A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Immediate, controlled and sustained release formulations of galantamine
EP2340813A1 (en) * 2003-12-31 2011-07-06 Actavis Group PTC ehf. Solid dosage formulations of galantamine
CA2552114A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Solid dosage formulations of galantamine
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020853A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
WO2006036686A2 (en) * 2004-09-24 2006-04-06 University Of Maryland, Baltimore Method of treating organophosphorous poisoning
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
NZ589750A (en) 2004-10-21 2012-07-27 Aptalis Pharmatech Inc Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
CA2590533C (en) * 2004-11-23 2010-09-07 Warner-Lambert Company Llc 7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia
US20080145422A1 (en) * 2005-02-10 2008-06-19 Roxane Laboratories, Inc. Galantamine tablet formulation
US9161918B2 (en) * 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
GB0516604D0 (en) * 2005-08-12 2005-09-21 Sandoz Ag Rapidly dispersing/disintegrating compositions
US8168219B2 (en) * 2005-11-30 2012-05-01 Isp Investments Inc. Synergistic binder composition, method for making same, and tablets of an active and said binder having advantageous hardness and friability
CA2646942C (en) 2006-03-16 2014-07-29 Niconovum Ab Improved snuff composition
NZ703464A (en) * 2006-04-26 2016-05-27 Alphapharm Pty Ltd Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
GB0612540D0 (en) * 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
EP2043613A1 (en) * 2006-07-14 2009-04-08 Fmc Corporation Solid form
CN100438917C (en) * 2006-07-20 2008-12-03 山东聊城阿华制药有限公司 Process for preparing micro crystal cellulose milk sugar
WO2008062426A2 (en) * 2006-08-02 2008-05-29 Emcure Pharmaceuticals Limited Formulation of benzazepine derivatives
MX2009004516A (en) 2006-10-27 2009-08-12 Medivation Neurology Inc Methods and combination therapies for treating alzheimer's disease.
US20080311162A1 (en) * 2007-05-16 2008-12-18 Olivia Darmuzey Solid form
PE20091156A1 (en) * 2007-12-17 2009-09-03 Astrazeneca Ab SALTS OF (3 - {[[3- (6-AMINO-2-BUTOXY-8-OXO-7,8-DIHIDRO-9H-PURIN-9-IL) PROPYL] (3-MORFOLIN-4-ILPROPIL) AMINO] METHYL} PHENYL) METHYL ACETATE
ATE545410T1 (en) 2008-05-09 2012-03-15 Ratiopharm Gmbh CONTROLLED RELEASE MEDICINAL CONTAINING GALANTHAMIN
ES2668203T3 (en) 2009-12-02 2018-05-17 Adare Pharmaceuticals S.R.L. Fexofenadine microcapsules and compositions containing them
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
JP5656258B2 (en) * 2011-03-09 2015-01-21 塩野義製薬株式会社 Orally disintegrating tablets containing galantamine
CA2921308A1 (en) 2013-08-16 2015-02-19 Universiteit Maastricht Treatment of cognitive impairment with pde4 inhibitor
CN106822008A (en) * 2017-01-11 2017-06-13 江苏艾兰得营养品有限公司 A kind of vitamin D dissolution formulation and preparation method thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3506276C1 (en) * 1985-02-22 1986-04-24 Meggle Milchindustrie Gmbh & Co Kg, 8094 Reitmehring Direct tableting
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
US6150354A (en) * 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
NZ242744A (en) * 1991-05-14 1997-02-24 Ernir Snorrason Use of a cholinesterase inhibitor (eg a galanthamine derivative) for treating fatigue
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
TW506836B (en) * 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet

Also Published As

Publication number Publication date
US6358527B1 (en) 2002-03-19
SI0915701T1 (en) 2005-06-30
ID17088A (en) 1997-12-04
AR070670A2 (en) 2010-04-28
DE69732113D1 (en) 2005-02-03
HRP970321A2 (en) 1998-04-30
CA2257431A1 (en) 1997-12-18
US6099863A (en) 2000-08-08
CN1222077A (en) 1999-07-07
CZ403498A3 (en) 1999-03-17
DK0915701T3 (en) 2005-04-25
EA199900026A1 (en) 1999-06-24
IL127519A0 (en) 1999-10-28
CN1102390C (en) 2003-03-05
ZA975281B (en) 1998-12-14
UA62930C2 (en) 2004-01-15
WO1997047304A1 (en) 1997-12-18
EP0915701A1 (en) 1999-05-19
BG102991A (en) 1999-08-31
TR199802592T2 (en) 1999-03-22
PL330431A1 (en) 1999-05-10
ES2235234T3 (en) 2005-07-01
SK169698A3 (en) 1999-10-08
NO985815D0 (en) 1998-12-11
BG64168B1 (en) 2004-03-31
EA001193B1 (en) 2000-12-25
JP2000511918A (en) 2000-09-12
NO322892B1 (en) 2006-12-18
CZ295226B6 (en) 2005-06-15
PT915701E (en) 2005-05-31
HK1019703A1 (en) 2000-02-25
BR9709729A (en) 1999-08-10
DE69732113T2 (en) 2005-12-08
AR008237A1 (en) 1999-12-29
MY121669A (en) 2006-02-28
AU726212B2 (en) 2000-11-02
NZ333280A (en) 1999-09-29
PL189329B1 (en) 2005-07-29
KR20000015851A (en) 2000-03-15
TW506836B (en) 2002-10-21
AU3174397A (en) 1998-01-07
HRP970321B1 (en) 2001-12-31
JP4172820B2 (en) 2008-10-29
CA2257431C (en) 2001-11-20
NO985815L (en) 1998-12-11
KR100358676B1 (en) 2003-02-17
SK284620B6 (en) 2005-07-01
ATE285777T1 (en) 2005-01-15
EP0915701B1 (en) 2004-12-29
IL127519A (en) 2002-07-25

Similar Documents

Publication Publication Date Title
EE03337B1 (en) Fast soluble galantamine hydrobromide tablet
ATE323682T1 (en) ARYL-PYRIMIDINE DERIVATIVES
DK0891332T3 (en) 6-phenylpyridyl-2-amine derivatives
ID24329A (en) MOBILE-FLOOR FOUNDATION
ATE367150T1 (en) DRUG
NO981946D0 (en) Imidazoquinazolin derivatives
DE69732576D1 (en) TETRAHYDROBENZINDOLON DERIVATIVES
DE69730434D1 (en) Immune-stimulating lipid formulation
DE59706429D1 (en) Leveler
BR9703096A (en) Hydraulic oscillator
NL1006015A1 (en) Administration device.
DE59706845D1 (en) Trench cutter
DE59703450D1 (en) TABLET TESTER
EE9900182A (en) 2-methoxyphenylpiperazine derivatives
NO983259L (en) Famciclovir tablets
TR199700071A2 (en) Tetrahydroisoquinoline derivatives.
KR970053768U (en) tablet
ES1027529Y (en) PERFECTED PLUG BASE.
UA1330S (en) DEPTH RING STAMP
BR9604141A (en) Mobile crushing set
BR7600438U (en) Tablet cutter
UA1246S (en) PHARMACEUTICAL TABLET
IT241819Y1 (en) SUCTION TABLET
ITPD960046A3 (en) SUCTION TABLET
ATA207996A (en) Manhole base

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231